Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Anti-depressants Boost Brain Cells After Injury

April 19, 2011 7:44 am | News | Comments

A new study was begun after neurosurgeons noticed that patients with brain injuries who had been prescribed anti-depressants were doing better in unexpected ways than their counterparts who were not taking such medications.


Injection Could Limit Heart Attack-Stroke Damage

April 19, 2011 7:40 am | News | Comments

Medical researchers held out promise that a simple injection is being developed to limit the devastating consequences of heart attacks and strokes. Work has already begun to translate the research into novel clinical therapies.


Phase 2 BC-3781 Trial Complete

April 19, 2011 7:34 am | News | Comments

Nabriva Therapeutics announced the successful results of a Phase 2 clinical trial of BC-3781 in acute bacterial skin and skin structure infections. BC-3781 is the first of a new class of systemically available pleuromutilin antibiotics.


Amarin's ANCHOR Trial Successful

April 19, 2011 7:27 am | News | Comments

Amarin Corporation plc reported positive top-line results from its ANCHOR trial for the Company’s lead product candidate, AMR101. The Phase 3 trial met its primary and secondary efficacy endpoints for both the 4 gram and 2 gram daily doses.


Lilly to Meet Cost-Cutting Goals

April 19, 2011 7:12 am | News | Comments

Eli Lilly and Co. is poised to meet or exceed its goals of cutting annual costs by $1 billion and eliminating 5,500 jobs, Chief Financial Officer Derica Rice said following the drugmaker's first-quarter earnings report.


Synthes Deal Would Brighten J & J Future

April 19, 2011 7:10 am | by Linda A. Johnson | News | Comments

Health giant Johnson & Johnson could boost its revenue and profit in the short term by buying Switzerland's Synthes Inc., while quickly gaining a dominant position in the growing market for orthopedic surgery products.


Valeant Responds to FDA Request on Ezogabine

April 19, 2011 7:07 am | News | Comments

Valeant Pharmaceuticals and GlaxoSmithKline have responded to a Food and Drug Administration request for more information on a potential epilepsy drug candidate, but did not provide more details on the information they provided.


Amylin Revenue Off 12%

April 19, 2011 7:04 am | News | Comments

Diabetes drug maker Amylin Pharmaceuticals Inc. reported a slightly narrower first-quarter loss as the company cut back on costs, offsetting a drop in revenue.


Novartis' Q1 Earnings Down 6%

April 19, 2011 7:02 am | by Frank Jordans | News | Comments

Swiss drug maker Novartis AG reported a 6 percent drop in first-quarter net profits as the cost of purchasing its remaining stake in eye care company Alcon depressed earnings.


Growth in Prescription Drug Use Continues to Slow

April 19, 2011 7:00 am | by Linda A. Johnson | News | Comments

Spending on prescription drugs in the U.S. grew relatively slowly last year as fewer people started new prescriptions and more prescriptions were filled with cheaper generics, an industry study shows.


J & J Profit Plummets 23%

April 19, 2011 6:59 am | by Linda A. Johnson | News | Comments

Health care giant Johnson & Johnson said its sales rebounded but its profit dropped 23 percent in the first quarter, due to higher expenses, costs of recalls and litigation and a tax gain that boosted results a year ago.


Vacuum Nest

April 18, 2011 8:14 am | Product Releases | Comments

Hudson Robotics announces the VaryVac, a robotically-controlled vacuum nest for filter plates. VaryVac has a unique combination of automated lid opening and sealing and precise closed-loop control of programmable vacuum levels.



April 18, 2011 8:11 am | Product Releases | Comments

The Pico200 from Micronic North America is a spectrophotometer that utilizes a unique patented design allowing UV/Vis measurements to be taken directly through a specialized pipette (UVpette) tip.


Baxter to Buy Prism for $338M

April 18, 2011 8:01 am | News | Comments

Baxter International Inc. has agreed to acquire Prism Pharmaceuticals, Inc. Prism Pharmaceuticals has received U.S. Food and Drug Administration approval for multiple presentations of NEXTERONE, an antiarrhythmic agent.


Promising Target for Lung Diseases Found

April 18, 2011 7:47 am | News | Comments

A researcher has discovered a molecule's role as a major trigger for airway remodeling, which impairs lung function, making the molecule a promising therapeutic target for chronic asthma, COPD, and several other lung conditions.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.